AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.

Authors

Florian Heitz

AGO Study Group & Ev. Kliniken Essen-Mitte, Essen, Germany

Florian Heitz , Christian Marth , Stephanie Henry , Alexander Reuss , David Cibula , Lydia Gaba , Nicoletta Colombo , Sandra Polleis , Philipp Harter

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.

First Author: Elena Ioana Braicu

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644).

First Author: Jean Emmanuel Kurtz

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Population-adjusted indirect treatment comparison (PAITC) of maintenance PARP inhibitor (PARPi) with or without bevacizumab versus bevacizumab in women with newly diagnosed ovarian cancer (OC).

First Author: Robert Hettle

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).

First Author: Shannon Neville Westin